Outlook Therapeutics, Inc (NASDAQ:OTLK) Lawrence Kenyon updated Proactive on the Monmouth, New Jersey-based biotech group's recent clinical advances. Kenyon says the group, who recently reported a positive safety profile in its NORSE THREE open-label safety study to treat wet AMD, says the group is almost complete with its pivotal Phase 3 NORSE TWO trial, expected to report that data in 3Q of 2021. Later within the year, it will then submit a BLA filing.
Outlook Therapeutics 'almost complete' with pivotal Phase 3 NORSE TWO trial to treat wet AMD
Quick facts: Outlook Therapeutics
Price: 2.38 USD
Market Cap: $417.31 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE